Filter posts
By category
Tag: ICER
Hits to Patients Keep on Coming
At a time when prescription drug prices and spending are remarkably stable, patients are getting …
BIO Communications Responds to Misleading Op-Ed about Medicaid Drug Costs
This week, Dr. Peter Bach of Memorial Sloan-Kettering Cancer Center authored an op-ed about the …
ICER Comes Under Renewed Scrutiny
As we enter a new and exciting era of medicine, there is an important question …
Value Assessment Tools that take “Precision” out of “Precision Medicine” are Harmful to Pati...
The conversation about health care costs is front and center in Washington, and new data …
Five Oncologists Weigh in on Value Frameworks
Value Frameworks, which attempt to quantify the value of a medicine, have been a hot …
Despite Latest Report, ICER Still Limits Patient Input and Maintains Strong Ties To Insurers
After months of criticism, including some from BIO, the Institute for Clinical and Economic Review …
ICER’s Methodology Needs to Take Into Account Key Stakeholder Voices
Last week, the Institute for Clinical and Economic Review (ICER) released the scoping document for …
ICER's Flawed Methodology Could Lead To Healthcare Rationing
In a column published in USA Today recently, Jeff Stier, a Senior Fellow at the …